| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/20/2001 | EP1108016A2 Mapkap kinase 2-inhibitors and the use thereof in anti-inflammatory therapy |
| 06/20/2001 | EP1108008A1 Novel ubiquitin ligases as therapeutic targets |
| 06/20/2001 | EP1107998A2 Polyamide chains of precise length, methods to manufacture them and their conjugates with proteins |
| 06/20/2001 | EP1107987A2 Novel irap-bp polypeptide and nucleic acid molecules and uses therefor |
| 06/20/2001 | EP1107986A1 Protein domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 and methods of making and using the same |
| 06/20/2001 | EP1107977A1 Ratc |
| 06/20/2001 | EP1107799A1 Method for labeling biopolymers using isotopes |
| 06/20/2001 | EP1107797A2 Hypoxia regulated genes |
| 06/20/2001 | EP1107795A2 Methods and compositions for the prevention or treatment of cancer |
| 06/20/2001 | EP1107794A2 Recombinant botulinium toxin for the treatment of mucus hypersecretion |
| 06/20/2001 | EP1107790A1 Targeting of molecules to large vessel endothelium using epcr |
| 06/20/2001 | EP1107788A1 Scrp-5: secreted cysteine rich protein-5 |
| 06/20/2001 | EP1107784A2 Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents |
| 06/20/2001 | EP1107780A2 Selective treatment of endothelial somatostatin receptors |
| 06/20/2001 | EP1107775A1 Composition containing pyrrolizidine-alkaloid-free petasites |
| 06/20/2001 | EP1107774A1 Ramp2a: receptor activity modifying protein-2a |
| 06/20/2001 | EP1107772A2 Probiotic, lactic acid-producing bacteria and uses thereof |
| 06/20/2001 | EP1107758A2 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
| 06/20/2001 | EP1107753A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 06/20/2001 | EP1107752A1 Pyrrolidine derivatives for vision and memory disorders |
| 06/20/2001 | EP1107749A2 The use of fumaric acid derivatives in transplant medicine |
| 06/20/2001 | EP1107747A1 Therapies for treating pulmonary diseases |
| 06/20/2001 | EP1107746A2 Methods of using and compositions comprising dopamine reuptake inhibitors |
| 06/20/2001 | EP1107745A1 Use of 5ht-6 antagonists |
| 06/20/2001 | EP1107744A2 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 06/20/2001 | EP1107741A1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 06/20/2001 | EP1107738A1 Novel pharmaceutical salt form |
| 06/20/2001 | EP1107733A1 Oral liquid mucoadhesive compositions |
| 06/20/2001 | EP1107702A1 Ultrasonic enhancement of drug injection |
| 06/20/2001 | EP0686037B1 Hormone replacement therapy |
| 06/20/2001 | CN1300224A Protease inhibitors in absorbent articles |
| 06/20/2001 | CN1300223A Disposable absorbent article having a skin care composition containing an enzyme inhibitor |
| 06/20/2001 | CN1300221A Treatment of cardiao hypertrophy |
| 06/20/2001 | CN1300218A Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 06/20/2001 | CN1300208A Icecream-type pharmaceutical formulation and process for preparing the same |
| 06/19/2001 | US6248872 Nucleotide sequences which code enzymatic protein; for use in detection and treatment of dirofilaria infection |
| 06/19/2001 | US6248867 Polypeptide associated with proper eye function; for the diagnosis of vision defects |
| 06/19/2001 | US6248791 Stimulating the differentiation of preadipocytic cells and therapies based thereon |
| 06/19/2001 | US6248784 Infant formula and methods of improving infant stool patterns |
| 06/19/2001 | US6248779 Synergistic mixture of vitamin e and squalane |
| 06/19/2001 | US6248752 Azabicyclooctane compositions and methods for enhancing chemotherapy |
| 06/19/2001 | US6248751 Inhibition of hair growth |
| 06/19/2001 | US6248749 Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation |
| 06/19/2001 | US6248735 Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist |
| 06/19/2001 | US6248729 Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination |
| 06/19/2001 | US6248727 Systemically administered diagnostic reagent for visualizing and occluding a blood vessel in a mammal comprising a liposome-encapsulated fluorescent dye releaseable at body temperature, a tissue reactive agent and a carrier |
| 06/19/2001 | US6248718 Lesion-directed dry dosage forms of antibacterial agents for the treatment of acute mucosal infections of the oral cavity |
| 06/19/2001 | US6248717 Tartrate salt of a substituted dipeptide as growth hormone secretagogue |
| 06/19/2001 | US6248712 Urokinase-type plasminogen activator receptor |
| 06/19/2001 | US6248594 Kinesin-like motor protein |
| 06/19/2001 | US6248576 Histidinol dehydrogenase |
| 06/19/2001 | US6248556 Nucleotide sequence of guanosine triphosphate-binding protein from staphylococcus; diagnosis of infections; drug screening; bactericides; bacteriostats; vaccines; probes; primers; vectors; host cells |
| 06/19/2001 | US6248532 Detecting modulators of regulatory element; incubate nucleotide sequences with modulators, monitor binding to nucleotide sequences, comparing binding in the presence and absence modulators |
| 06/19/2001 | US6248528 Drug screening by contacting test compound with human centrin protein and determining whether compound binds to protein |
| 06/19/2001 | US6248390 Fiber-water—water containing soluble fiber |
| 06/19/2001 | US6248345 Prolonged anesthesia in joints and body spaces |
| 06/19/2001 | US6248341 Method of treating topical angiogenesis-related disorders |
| 06/19/2001 | US6248335 Ph control |
| 06/19/2001 | US6248327 Using antibody |
| 06/19/2001 | US6248326 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
| 06/19/2001 | US6248308 Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma |
| 06/19/2001 | US6248057 Absorbable brachytherapy and chemotherapy delivery devices and methods |
| 06/19/2001 | CA2172187C Method of incorporating drugs into a polymer component of stents |
| 06/19/2001 | CA2040248C Method of inhibiting gastric acid secretion |
| 06/14/2001 | WO2001042794A2 Method for identifying inhibitors of cytokinesis |
| 06/14/2001 | WO2001042784A2 Methods for screening compounds active on neurons |
| 06/14/2001 | WO2001042506A1 T1 receptor-like ligand ii and uses thereof |
| 06/14/2001 | WO2001042488A2 Plasminogen activator assay involving an elastase inhibitor |
| 06/14/2001 | WO2001042307A1 MUTANT ERα AND TEST SYSTEMS FOR TRANSACTIVATION |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042285A2 Extracellular matrix and cell adhesion proteins as well as genes encoding them |
| 06/14/2001 | WO2001042263A2 Oligosaccharide mixture |
| 06/14/2001 | WO2001042255A1 (1R,CIS)-4-(4-AMINO-7H-PYRROLO'2,3-I(D) ! PYRIMIDINE-7-YL)-2-CYCLOPENTENE-1-METHANOL DERIVATIVES AS ANTIVIRAL |
| 06/14/2001 | WO2001042246A2 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042207A2 Novel methods for the treatment and prevention of ileus |
| 06/14/2001 | WO2001042189A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 06/14/2001 | WO2001042181A1 Benzyl tetralins, formulations and uses thereof |
| 06/14/2001 | WO2001041823A2 Radioactive compositions and methods of use thereof |
| 06/14/2001 | WO2001041807A2 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 06/14/2001 | WO2001041803A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-α AND CD95L IN A MEDICAMENT |
| 06/14/2001 | WO2001041801A2 Mutant simplex virus for treating unwanted hyperproliferative cell growth |
| 06/14/2001 | WO2001041795A1 An additive for an animal feed |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041783A1 Methods and compositions for treatment of inflammatory disease |
| 06/14/2001 | WO2001041780A2 Use of an immunosuppressant for increasing an antifugal activity of a lipopeptide |
| 06/14/2001 | WO2001041778A1 Melanin synthesis inhibition compound and composition containing the same |
| 06/14/2001 | WO2001041771A2 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 06/14/2001 | WO2001041769A2 Combination of cyamemazine and an atypical neuroleptic |
| 06/14/2001 | WO2001041766A1 The combination of a serotonin reuptake inhibitor and irindalone |
| 06/14/2001 | WO2001041763A1 Treatment of addiction disorders |
| 06/14/2001 | WO2001041762A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041761A2 Valdecoxib compositions |
| 06/14/2001 | WO2001041760A2 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 06/14/2001 | WO2001041753A2 Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds |
| 06/14/2001 | WO2001041752A2 Use of isoform specific inhibitors of cgmp-dependent protein kinase for treatment of pain |
| 06/14/2001 | WO2001041750A2 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics |
| 06/14/2001 | WO2001041749A2 Combinations of sumatriptan or naratriptan with cyclooxygenase iiinhibitor |